NCT07838415

Brief Summary

This study aims to explore whether adding an additional MRI sequence to routine liver scans can better characterize the immune microenvironment of liver cancer. We plan to prospectively enroll patients diagnosed with or suspected of having liver cancer who undergo routine MRI examinations. In addition to the standard MRI protocol, participants will receive one extra MRI sequence. We will analyze the imaging features from this additional sequence and combine them with clinical data to construct a multi-omics model. The goal is to identify imaging biomarkers that can reflect the dynamic changes of the tumor microenvironment, which may help improve the diagnosis and clinical management of liver cancer.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
400

participants targeted

Target at P75+ for all trials

Timeline
21mo left

Started Oct 2024

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress55%
Oct 2024Jun 2028

Study Start

First participant enrolled

October 1, 2024

Completed
1.9 years until next milestone

First Submitted

Initial submission to the registry

August 10, 2026

Completed
2 months until next milestone

First Posted

Study publicly available on registry

September 24, 2026

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2027

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2028

Last Updated

September 24, 2026

Status Verified

September 1, 2026

Enrollment Period

2.7 years

First QC Date

August 10, 2026

Last Update Submit

September 22, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • The primary outcomes of this study were PFS

    PFS was calculated from the time of receiving treatment to disease progression or death, whichever occurred first, and progression was determined based on contrast-enhanced CT or MRI scans following mRECIST criteria

    Up to 24 months after baseline MRI

Interventions

Time-dependent Diffusion MRI: This is a specialized MRI technique that measures water molecule diffusion at different time intervals to probe tissue microstructural features. In tumor tissues with dense cellularity and complex architecture, water diffusion is restricted. This technique allows for the detection of changes in cell size, shape, and interstitial spaces in liver cancer, providing insights into tumor heterogeneity and microenvironment. CEST (Chemical Exchange Saturation Transfer): This is a molecular imaging technique based on chemical exchange. It selectively saturates exchangeable protons on specific molecules (such as proteins, peptides, or metabolites) and detects the transfer of this saturation effect to water protons, enabling indirect measurement of specific molecule concentrations in vivo. In liver cancer research, CEST can detect protein content, pH changes, and metabolic abnormalities in tumor tissues, providing functional information to assess tumor biological be

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Consecutive patients with suspected primary HCC detected on ultrasound or CT at our institution or referring hospitals were prospectively enrolled. All participants underwent EOB-MRI, including Td-dMRI and conventional sequences.

You may qualify if:

  • age 18 years or older, (b) pathologically confirmed HCC with available pathology slides, and (c) EOB-MRI including Td-dMRI within 1 month before surgery.

You may not qualify if:

  • (a) lesions smaller than 1 cm, (b) poor imaging quality, and (c) received other treatments before surgery.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tongji Hospital

Wuhan, Hubei, 430000, China

RECRUITING

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsLiver NeoplasmsDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesLiver Diseases

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
24 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chief Physician, Professor

Study Record Dates

First Submitted

August 10, 2026

First Posted

September 24, 2026

Study Start

October 1, 2024

Primary Completion (Estimated)

June 1, 2027

Study Completion (Estimated)

June 1, 2028

Last Updated

September 24, 2026

Record last verified: 2026-09

Locations